• Login
    Search 
    •   Home
    • The University of Manchester - Partnerships
    • Search
    •   Home
    • The University of Manchester - Partnerships
    • Search
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CommunityTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Filter by Category

    Subjects
    Colorectal Cancer (1)
    Thyroid Cancer (1)
    View MoreJournalBest Practice & Research. Clinical Endocrinology & Metabolism (1)AuthorsBrennan, Bernadette M (1)Renehan, Andrew G (1)
    Renehan, Andrew G (1)
    Year (Issue Date)2008-08 (1)TypesArticle (1)

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics
     

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Now showing items 1-1 of 1

    • List view
    • Grid view
    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100

    • 1CSV
    • 1RefMan
    • 1EndNote
    • 1BibTex
    • Selective Export
    • Select All
    • Help
    Thumbnail

    Acromegaly, growth hormone and cancer risk.

    Renehan, Andrew G; Brennan, Bernadette M (2008-08)
    Acromegaly is an endocrine disorder characterized by sustained hypersecretion of growth hormone (GH) with concomitant elevation of insulin-like growth factor I (IGF-I) associated with premature mortality from cardiopulmonary diseases and certain malignancies. In particular, there is a two-fold increased risk of developing colorectal cancer. Possible mechanisms underlying this association include elevated levels of circulating GH and IGF-I, but several other plausible processes may be relevant. In a parallel literature, there has been debate whether GH replacement therapy is associated with increased cancer risk in three scenarios: (1) tumour recurrence in children with previously treated cancer; (2) second neoplasms (SNs) in survivors of childhood cancer treated with GH; and (3) de-novo cancer in non-cancer patients treated with GH. The general evidence suggests no increased risk in scenario 1. Through a maze of complex study designs, there is inconclusive evidence of a very modest increase in cancer risk in treated GH-deficiency patients in scenarios 2 and 3, but it is likely that the cumulative risk equates to that of the general population. This emphasizes the need for patient selection balanced against the known morbidity of untreated GH deficiency.
    DSpace software (copyright © 2002 - 2019)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.